BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. Clin Gastroenterol Hepatol 2016;14:1035-43. [PMID: 27062903 DOI: 10.1016/j.cgh.2016.03.040] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 15.2] [Reference Citation Analysis]
Number Citing Articles
1 Kim AY. The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective. Clin Infect Dis 2017;65:709-11. [PMID: 28575213 DOI: 10.1093/cid/cix501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
3 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
4 Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, Thomas DL, Mehta SH. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int 2020;40:2407-16. [PMID: 32770638 DOI: 10.1111/liv.14634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. J Clin Oncol 2019;37:2105-19. [PMID: 31157579 DOI: 10.1200/JCO.18.02079] [Cited by in Crossref: 70] [Cited by in F6Publishing: 29] [Article Influence: 23.3] [Reference Citation Analysis]
6 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
7 Vu TM, Toribio W, Riazi F, Ciprian G, Gibbs N, Giardina M, Camacho JA, Parrella K, Cambe J, Amory C, Chasan R, Sigel KM, Weiss JJ. Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval. J Manag Care Spec Pharm 2018;24:329-33. [PMID: 29578854 DOI: 10.18553/jmcp.2018.24.4.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
8 Da BL, Ezaz G, Kushner T, Crismale J, Kakked G, Gurakar A, Dieterich D, Schiano TD, Saberi B. Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation. JAMA Netw Open 2020;3:e2027551. [PMID: 33275155 DOI: 10.1001/jamanetworkopen.2020.27551] [Reference Citation Analysis]
9 Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City. J Urban Health 2021;98:563-9. [PMID: 32016914 DOI: 10.1007/s11524-020-00422-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Adv Ther 2018;35:1087-102. [DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
11 Aqel B, Wijarnpreecha K, Pungpapong S, Taner CB, Reddy K, Leise M, Mi L, Dickson RC. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. Journal of Hepatology 2021;74:873-80. [DOI: 10.1016/j.jhep.2020.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Zuckerman A, Carver A, Chastain CA. Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes. Curr Treat Options Infect Dis. 2018;10:431-446. [PMID: 30524209 DOI: 10.1007/s40506-018-0177-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
13 Kumar SR, Khatana SAM, Goldberg D. Impact of Medicaid Expansion on Liver-Related Mortality. Clin Gastroenterol Hepatol 2022;20:419-426.e1. [PMID: 33278572 DOI: 10.1016/j.cgh.2020.11.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kossmeier M, Themanns M, Hatapoglu L, Kogler B, Keuerleber S, Lichtenecker J, Sauermann R, Bucsics A, Freissmuth M, Zebedin-Brandl E. Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria. Front Pharmacol 2021;12:726758. [PMID: 34483937 DOI: 10.3389/fphar.2021.726758] [Reference Citation Analysis]
15 Kaufman HW, Bull-Otterson L, Meyer WA 3rd, Huang X, Doshani M, Thompson WW, Osinubi A, Khan MA, Harris AM, Gupta N, Van Handel M, Wester C, Mermin J, Nelson NP. Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. Am J Prev Med 2021;61:369-76. [PMID: 34088556 DOI: 10.1016/j.amepre.2021.03.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rice DP, Ordoveza MA, Palmer AM, Wu GY, Chirch LM. Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients. AIDS Care 2018;30:1507-11. [PMID: 30021452 DOI: 10.1080/09540121.2018.1499857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant 2019;19:3058-70. [PMID: 31207073 DOI: 10.1111/ajt.15496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
18 Du P, Wang X, Kong L, Riley T 3rd, Jung J. Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017. Am J Prev Med 2021;60:285-93. [PMID: 33221144 DOI: 10.1016/j.amepre.2020.08.031] [Reference Citation Analysis]
19 Spiewak T, Taefi A, Patel S, Li CS, Chak E. Racial disparities of Black Americans hospitalized for decompensated liver cirrhosis. BMC Gastroenterol. 2020;20:245. [PMID: 32727386 DOI: 10.1186/s12876-020-01392-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
21 Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Coinfection Cohort Study Investigators. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis 2020;71:363-71. [PMID: 31504327 DOI: 10.1093/cid/ciz833] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
22 Kapadia SN, Gulick RM. Drug Costs: What Can Infectious Diseases Physicians Do? J Infect Dis 2020;221:681-4. [PMID: 30887031 DOI: 10.1093/infdis/jiz067] [Reference Citation Analysis]
23 Jiang X, Song HJ, Wang W, Henry L, Childs-Kean LM, Re VL 3rd, Park H. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. J Manag Care Spec Pharm 2021;27:873-81. [PMID: 34185563 DOI: 10.18553/jmcp.2021.27.7.873] [Reference Citation Analysis]
24 Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; Canadian Network on Hepatitis C (CanHepC). Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016;4:E605-14. [PMID: 28018873 DOI: 10.9778/cmajo.20160008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 9.2] [Reference Citation Analysis]
25 Miller LS, Millman AJ, Lom J, Osinubi A, Ahmed F, Dupont S, Rein D, Vellozzi C, Harris AM. Defining the hepatitis C cure cascade in an Urban health system using the electronic health record. J Viral Hepat 2020;27:13-9. [PMID: 31505088 DOI: 10.1111/jvh.13199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Res 2019;163:149-55. [PMID: 30711416 DOI: 10.1016/j.antiviral.2019.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Schwartz RE, Bram Y, Frankel A. Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease. Curr Pathobiol Rep 2016;4:147-56. [PMID: 29910973 DOI: 10.1007/s40139-016-0113-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Jain MK, Thamer M, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Wong RJ. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period? Hepatology 2019;69:51-63. [PMID: 30019478 DOI: 10.1002/hep.30171] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
29 Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol 2018;113:1329-38. [PMID: 29523864 DOI: 10.1038/s41395-018-0033-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
30 Malespin M, Harris C, Kanar O, Jackman K, Smotherman C, Johnston A, Ferm J, de Melo SW Jr, Scolapio JS, Nelson DR, Cotler SJ. Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. Ann Hepatol 2019;18:304-9. [PMID: 31053544 DOI: 10.1016/j.aohep.2018.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
31 Lau AA, Strebe JK, Sura TV, Hansen LA, Jain MK. Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.645] [Reference Citation Analysis]
32 Ooka K, Connolly JJ, Lim JK. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. Am J Gastroenterol 2017;112:828-32. [PMID: 28374816 DOI: 10.1038/ajg.2017.87] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
33 Lo Re V. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment. Clin Infect Dis 2017;64:498-500. [PMID: 28172488 DOI: 10.1093/cid/ciw814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Islami F, Siegel RL, Jemal A. The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment. Nat Rev Clin Oncol 2020;17:631-49. [DOI: 10.1038/s41571-020-0378-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Tenner L, Melhado TV, Bobadilla R, Turner BJ, Morgan R. The Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South Texas. J Oncol Pract 2019;15:61-3. [PMID: 30668219 DOI: 10.1200/JOP.18.00525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
36 Zuckerman A, Douglas A, Nwosu S, Choi L, Chastain C. Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era. PLoS One 2018;13:e0199174. [PMID: 29912944 DOI: 10.1371/journal.pone.0199174] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
37 Koren DE, Zuckerman A, Teply R, Nabulsi NA, Lee TA, Martin MT. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model. Open Forum Infect Dis. 2019;6. [PMID: 31363775 DOI: 10.1093/ofid/ofz316] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
38 Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, Butt ZA, Chong M, Cook D, Alvarez M, Darvishian M, Tyndall M, Krajden M. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. J Viral Hepat 2017;24:624-30. [DOI: 10.1111/jvh.12684] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
39 Gomes C, Ginzberg D, Wong RJ. Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience. J Transl Int Med 2020;8:261-7. [PMID: 33511053 DOI: 10.2478/jtim-2020-0039] [Reference Citation Analysis]
40 Prakash K, Ramirez-Sanchez C, Ramirez SI, Logan C, Law N, Mekeel K, Pretorius V, Aslam S. Post-transplant survey to assess patient experiences with donor-derived HCV infection. Transpl Infect Dis 2020;22:e13402. [PMID: 32634289 DOI: 10.1111/tid.13402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Marciano S, Haddad L, Borzi SM, D'Amico C, Gaite LA, Aubone MV, Sirotinsky ME, Ratusnu N, Frola MS, Aparicio MC, Ríos B, Anselmo MN, Hansen R, De Filippi S, Dans CG, de Labra L, Peche MA, Strella TM, Ibáñez Duran M, García Rosales MB, Dirchwolf M, Galdame OA, Gadano AC. Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources. Rev Gastroenterol Mex (Engl Ed) 2018;83:208-11. [PMID: 29656845 DOI: 10.1016/j.rgmx.2018.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Du P, Wang X, Kong L, Jung J. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents? Telemed J E Health. 2021;27:488-494. [PMID: 32882154 DOI: 10.1089/tmj.2020.0090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Goldberg D, Reese PP. Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus-infected donors into hepatitis C virus-negative patients. Semin Dial 2019;32:179-86. [DOI: 10.1111/sdi.12767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther 2018;40:1234-45. [PMID: 29983266 DOI: 10.1016/j.clinthera.2018.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
45 Radwan D, Cachay E, Falade-Nwulia O, Moore RD, Westergaard R, Mathews WC, Aberg J, Cheever L, Gebo KA; HIV Research Network. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015. J Acquir Immune Defic Syndr 2019;80:559-67. [PMID: 30649030 DOI: 10.1097/QAI.0000000000001949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
46 Wong JB, Cohen JT. Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost. Clin Gastroenterol Hepatol 2017;15:838-40. [PMID: 28259743 DOI: 10.1016/j.cgh.2017.02.026] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 van Boemmel-Wegmann S, Lo Re V 3rd, Park H. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Dig Dis Sci 2020;65:3159-74. [PMID: 31938995 DOI: 10.1007/s10620-019-06037-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd. Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 2020;15:e0228471. [PMID: 32023310 DOI: 10.1371/journal.pone.0228471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
49 Abutaleb A, Kottilil S. Vedroprevir in the management of hepatitis C virus infection. Expert Opin Investig Drugs 2017;26:1399-402. [PMID: 29053394 DOI: 10.1080/13543784.2017.1395412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Torabi J, Rocca JP, Ajaimy M, Melvin J, Campbell A, Akalin E, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Le M, Goldstein DY, Fox AS, Carrero J, Weiss JM, Powell T, Racine AD, Reinus JF, Kinkhabwala MM, Graham JA. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis. 2021;23:e13449. [PMID: 32810315 DOI: 10.1111/tid.13449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Geenen JW, Boersma C, Klungel OH, Hövels AM. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. Eur J Health Econ 2019;20:857-67. [PMID: 30953216 DOI: 10.1007/s10198-019-01048-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Liu X, Lee JL, Yoo JW. More Benefits From Interrupted Time Series in Evaluating the Recent Market Release of Direct-Acting Antiviral Agents and State Medicaid Reimbursement Programs. Clinical Gastroenterology and Hepatology 2017;15:1813. [DOI: 10.1016/j.cgh.2017.05.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Nakayama JY, Ho J, Cartwright E, Simpson R, Hertzberg VS. Predictors of progression through the cascade of care to a cure for hepatitis C patients using decision trees and random forests. Comput Biol Med 2021;134:104461. [PMID: 33975209 DOI: 10.1016/j.compbiomed.2021.104461] [Reference Citation Analysis]
54 Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther. 2018;47:1278-1287. [PMID: 29516535 DOI: 10.1111/apt.14593] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
55 Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 2017;33:120-7. [PMID: 28234770 DOI: 10.1097/MOG.0000000000000347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
56 Morales JM, Sawinski D. New insights into the rational use of HCV+ organs worldwide. Clin Transplant 2019;33:e13739. [PMID: 31648391 DOI: 10.1111/ctr.13739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Cohen JB, Eddinger KC, Shelton B, Locke JE, Forde KA, Sawinski D. Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes. Clin Kidney J 2017;10:564-72. [PMID: 28852496 DOI: 10.1093/ckj/sfx048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
58 Behrends CN, Eggman AA, Gutkind S, Bresnahan MP, Fluegge K, Laraque F, Litwin AH, Meissner P, Shukla SJ, Perumalswami PV, Weiss J, Wyatt BE, Schackman BR. A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination. J Public Health Manag Pract 2019;25:253-61. [PMID: 29975342 DOI: 10.1097/PHH.0000000000000806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Collins LF, Chan A, Zheng J, Chow SC, Wilder JM, Muir AJ, Naggie S. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. Open Forum Infect Dis 2018;5:ofx264. [PMID: 29308413 DOI: 10.1093/ofid/ofx264] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
60 Kapadia SN, Johnston CD, Marks KM, Schackman BR, Martin EG. Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. J Public Health Manag Pract 2019;25:245-52. [PMID: 29927900 DOI: 10.1097/PHH.0000000000000829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
61 Deming R, Ford MM, Moore MS, Lim S, Perumalswami P, Weiss J, Wyatt B, Shukla S, Litwin A, Reynoso S, Laraque F. Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach. J Viral Hepat 2018;25:1236-43. [PMID: 29757491 DOI: 10.1111/jvh.12929] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
62 Park H, Song HJ, Jiang X, Henry L, Cook RL, Nelson DR. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C. Hepatol Commun 2021;5:203-16. [PMID: 33553969 DOI: 10.1002/hep4.1634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer 2020;127:45-55. [PMID: 33103243 DOI: 10.1002/cncr.33211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Aliment Pharmacol Ther 2020;51:1384-96. [PMID: 32352586 DOI: 10.1111/apt.15707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation 2020;104:476-81. [PMID: 31634329 DOI: 10.1097/TP.0000000000003014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
66 Gowda C, Lo Re V 3rd. Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. Curr Hepatol Rep 2018;17:111-20. [PMID: 30294518 DOI: 10.1007/s11901-018-0394-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
67 Geenen JW, Belitser SV, Vreman RA, van Bloois M, Klungel OH, Boersma C, Hövels AM. A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. Eur J Health Econ 2020;21:845-53. [PMID: 32248313 DOI: 10.1007/s10198-020-01176-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Zuckerman AD, Douglas A, Whelchel K, Choi L, DeClercq J, Chastain CA. Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter? PLoS One. 2019;14:e0225434. [PMID: 31751399 DOI: 10.1371/journal.pone.0225434] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
69 Spradling PR, Xing J, Rupp LB, Moorman AC, Gordon SC, Lu M, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015. J Clin Gastroenterol 2018;52:641-7. [PMID: 28590325 DOI: 10.1097/MCG.0000000000000857] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
70 Terrault NA. Hepatitis C elimination: challenges with under-diagnosis and under-treatment. F1000Res. 2019;8:F1000 Faculty Rev-54. [PMID: 30687501 DOI: 10.12688/f1000research.15892.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
71 Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, Stoller K, Thomas DL, Latkin C, Mehta SH. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat 2019;100:45-51. [PMID: 30898327 DOI: 10.1016/j.jsat.2019.01.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
72 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Forde KA, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd. The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. PLoS One 2021;16:e0258143. [PMID: 34610030 DOI: 10.1371/journal.pone.0258143] [Reference Citation Analysis]
73 McLean RC, Reese PP, Acker M, Atluri P, Bermudez C, Goldberg LR, Abt PL, Blumberg EA, Van Deerlin VM, Reddy KR, Bloom RD, Hasz R, Suplee L, Sicilia A, Woodards A, Zahid MN, Bar KJ, Porrett P, Levine MH, Hornsby N, Gentile C, Smith J, Goldberg DS. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial. Am J Transplant 2019;19:2533-42. [PMID: 30768838 DOI: 10.1111/ajt.15311] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
74 Harris AM, Khan MA, Osinubi A, Nelson NP, Thompson WW. Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014-2018. Am J Prev Med 2021:S0749-3797(21)00348-2. [PMID: 34362617 DOI: 10.1016/j.amepre.2021.05.017] [Reference Citation Analysis]
75 Nguyen P, Vutien P, Hoang J, Trinh S, Le A, Yasukawa LA, Weber S, Henry L, Nguyen MH. Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience. BMJ Open Gastroenterol 2017;4:e000181. [PMID: 29333275 DOI: 10.1136/bmjgast-2017-000181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
76 Vo QT, Onofrey S, Church D, Cranston K, DeMaria A, Klevens RM. The Massachusetts Hepatitis C Testing Cascade, 2014-2016. Microbiol Insights 2019;12:1178636119857961. [PMID: 31258329 DOI: 10.1177/1178636119857961] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Haley DF, Edmonds A, Ramirez C, French AL, Tien P, Thio CL, Witt MD, Seaberg EC, Plankey MW, Cohen MH, Adimora AA. Direct-Acting Antiviral Hepatitis C Treatment Cascade and Barriers to Treatment Initiation Among US Men and Women With and Without HIV. J Infect Dis 2021;223:2136-44. [PMID: 33141170 DOI: 10.1093/infdis/jiaa686] [Reference Citation Analysis]
78 McLaughlin MM, Marx KT, Terriff C; American Academy of HIV Medicine Pharmacists Committee. Improving patient access to hepatitis C virus treatment. J Am Pharm Assoc (2003) 2018;58:109-112.e1. [PMID: 29154018 DOI: 10.1016/j.japh.2017.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
79 Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790-2802. [PMID: 28556422 DOI: 10.1111/ajt.14381] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 40.4] [Reference Citation Analysis]
80 Sawinski D, Forde KA, Locke JE, Cohen JB, Weldon J, Shults J, Reese PP. Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int 2018;93:706-15. [PMID: 29107361 DOI: 10.1016/j.kint.2017.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
81 Javanbakht M, Archer R, Klausner J. Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system. PLoS One 2020;15:e0241615. [PMID: 33147293 DOI: 10.1371/journal.pone.0241615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd. Determinants of stigma among patients with hepatitis C virus infection. J Viral Hepat 2020;27:1179-89. [PMID: 32500618 DOI: 10.1111/jvh.13343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
83 Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol 2016;4:310-9. [PMID: 28097100 DOI: 10.14218/JCTH.2016.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]
84 Schranz AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C. Curr HIV/AIDS Rep 2018;15:245-54. [PMID: 29796965 DOI: 10.1007/s11904-018-0393-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
85 Daniel Moore J, Galbraith J, Humphries R, Havens JR. Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department. Open Forum Infect Dis 2021;8:ofab374. [PMID: 34381848 DOI: 10.1093/ofid/ofab374] [Reference Citation Analysis]
86 Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis 2018;5:ofy076. [PMID: 29977955 DOI: 10.1093/ofid/ofy076] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
87 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
88 Palaniswami PM, El Sayed A, Asriel B, Carollo JR, Fierer DS; New York Acute Hepatitis C Surveillance Network . Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men. Open Forum Infect Dis 2018;5:ofy238. [PMID: 30349848 DOI: 10.1093/ofid/ofy238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
89 Vutien P, Jin M, Le MH, Nguyen P, Trinh S, Huang JF, Yu ML, Chuang WL, Nguyen MH. Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. PLoS One 2017;12:e0183851. [PMID: 28877190 DOI: 10.1371/journal.pone.0183851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]